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Objective: The objective of this EBM review is to determine whether or not the use of 
mesalamine decreases abdominal pain in adults with IBS. 
 
Study Design: Review of 3 randomized control trials. 
Data Sources: All articles were published in English between 2012 and 2016. Articles were 
obtained from peer-reviewed journals using PubMed. 
 
Outcomes: The outcome measured was the level or presence of abdominal and was measured 
via binary scale, 10-point visual analogue scale rated by patients on a 0 to 10 scale with 0 being 
no pain and 10 being the maximum level of pain and via patient symptom diary questionnaire. 
 
Results: Barbara et al. showed that mesalazine reduced abdominal pain and discomfort superior 
to placebo in patients with IBS, but this was not statistically significant, with a p-value of 0.404. 
Tuteja et al. showed that mesalamine was superior to placebo at reducing abdominal pain from 
baseline in patients with post-infective IBS, but this was not statistically significant, with a p-
value of 0.83. Lam et al. showed that mesalazine did not decrease abdominal pain in patients 
with IBS-D superior to placebo, with a p-value of 0.83. 
 
Conclusions: All three articles used mesalazine to treat abdominal pain and used placebo as the 
control group. Although two articles showed that mesalamine can decrease abdominal pain at a 
superior level to placebo, the results we not clinically significant. The third trial showed that 
mesalamine was not superior to placebo in decreasing abdominal pain. Further studies and 
perhaps larger studies are needed to determine if mesalamine can have a statistically significant 
impact on decreasing abdominal pain.  
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Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder 
characterized by abdominal pain with disorder in defecation and stool consistency in the absence 
of another cause for these symptoms.1 It is the most common function bowel disorder and can be 
encountered in a variety of practice settings.2 Physicians as well as physician assistants may 
encounter the disorder in the settings in which they work. It is diagnosed based on the Rome IV 
criteria which states that abdominal pain must be present at least once a day for at least three 
months and must include two or more of the following criteria: related to defecation, change in 
the appearance of the stool, or change in the frequency of the stool. There are two main types of 
IBS, IBS-D, which is diarrhea predominant and IBS-C, which is constipation predominant. 
Patients may also suffer from a combination of both which is categorized as mixed with 
alternating diarrhea and constipation. Symptoms of the disorder include bloating, diarrhea, 
constipation, excessive flatulence, and abdominal pain.1 Abdominal pain and discomfort are 
hallmark symptoms of the disorder and are usually one of the symptoms that drive patients to 
seek medical attention.2  
The disorder is associated with comorbid conditions including psychiatric conditions 
such as anxiety and depression, and visceral hypersensitivity.3 There has also been shown to be a 
genetic link to the disorder, with patients who have a family history being predisposed to 
developing IBS at some point in their lifetime.2 Despite these associations the pathophysiology if 
IBS is still poorly understood and mainly considered to be idiopathic.4  
The symptoms patients with IBS experience can have an immense impact on their quality 
of life. An article in Expert Opin estimated that in 2015 the US lost $205 million in productivity 
due to IBS.5 IBS has a marked impact on the healthcare system as well. The total cost of 




healthcare visits in the US for IBS was estimated by Aran Ediciones to be $20,000,000 yearly in 
2016 which includes the cost of laboratory and diagnostic studies needed to rule out other 
conditions.6 IBS is the reason for greater than 3.5. million office visits each year in the US.6  
IBS is traditionally treated with pharmacological and non-pharmacological treatment 
methods. Non-pharmacological treatments include psychotherapy, exercise, and  diet 
modification which includes avoiding triggers e.g., FODMAP diet, increasing fiber intake, and 
addressing lactose intolerance.4 Pharmacotherapy is targeted at symptomatic treatment. 
Antispasmodic agents such as dicyclomine and hyoscyamine are used to ease abdominal pain 
and decrease visceral hypersensitivity. Peppermint oil capsules are also used as an antispasmodic 
agent. Low dose tri-cyclic antidepressants and SSRIs are also used for treating abdominal pain as 
well as other symptoms.4 For IBS-C lubiprostone and linaclotide are used to treat constipation by 
increasing serotonin levels, aiding in bowel movement regularity. Bulking agents such as 
psyllium and osmotic laxatives such as polyethylene glycol are used to attract water to the lumen 
of the colon aiding in stool passage. For IBS-D loperamide and diphenoxylate atropine are used 
as antidiarrheals. In rare cases antibiotics may also be used if the onset of IBS is after an acute 
case of gastroenteritis. These cases are deemed as post-infective IBS.1 
Mesalamine also known as mesalazine is a topical salicylate that is used as a treatment 
for ulcerative colitis to decrease bowel inflammation. It has been previously found that patients 
with IBS can exhibit low levels of inflammation in bowel mucosa especially after acute cases of 
gastroenteritits.2 According to a study published in the British Medical Journal up to 36.8% of 
subjects developed IBS following recovery from acute infectious gastroenteritis, suggesting the 
possibility that IBS has an inflammatory etiology.2 Other factors can also contribute to this low-
grade inflammation including stress, atopy, genetics, and various other factors.2 Since it has 




already been demonstrated that patients with IBS can have low levels of inflammation in GI 
mucosa including inflammatory markers and immune cells and a study has been previously 
demonstrated that mesalamine decreased inflammatory markers and immune cells in the bowel 
mucosa of patients with IBS intuitively using the anti-inflammatory mesalamine to treat the 
symptoms of the disorder may be the solution to treating the underlying cause of IBS instead of 
simply treating the disorder symptomatically.2   
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not mesalamine 
decreases abdominal pain in patients with IBS when compared to placebo. 
METHODS 
The studies used in this review were found by searching PubMed using the keywords 
“irritable bowel syndrome” and “mesalamine”.  The studies selected for this review fit the 
clinical topic selected and the results measured were Patient-Oriented Evidence that Matters 
(POEMs). The studies selected consisted of randomized control human trials published after 
2009. All other studies including non-human studies were excluded. Table 1 presents inclusion 
and exclusion criteria for each individual study. After review of criteria, 3 studies were selected 
for this review. All of the studies were written in English and were obtained from a peer-
reviewed journals. 
The population studied were adults, 18 years and older. The intervention used was 
mesalamine. The comparison group for each study was placebo. Each study used various doses 
of the drug. Barbara et al. used 800 mg of mesalazine three times daily  for 12 weeks, Tuteja et 
al. used 1.6 g of mesalamine twice daily for 12 weeks, and lastly Lam et al. used 2 g of 
mesalazine daily for one week then twice daily for 11 weeks. The outcome measured from all 




three studies was the subjective decrease in abdominal pain intensity. Pain intensity was 
measured using a binary scale in Barbara et al. and a scale of 0 to 10 for Lam et al. In the Tuteja 
et al. study, participants rated their abdominal pain as none, minimal, mild, moderate, or severe. 
Statistical significance of each study’s results was reported as p-values.  
OUTCOMES MEASURED 
 
Outcome measured for all 3 studies was the participants’ subjective decrease in 
abdominal pain. Outcomes from the different studies were measured via 10-point visual analogue 
scale labeled 0 to 10 with 0 being no pain and 10 being the maximum level of pain. One study 
also used patient symptom diary questionnaire where the participant was asked their level of pain 
and rated it as none, minimal, mild, moderate or severe.1  
RESULTS 
Barbara et al. (2016) performed a randomized control trial comparing the use of 800 mg 
of oral mesalazine to placebo. The population for this study were adults 18-65 with a diagnosis 
of any IBS subtype and was mostly made up of Caucasian females.2 The participants were 
recruited from 21 Italian centers.2 The full inclusion and exclusion criteria for this study can be 
found in Table 1. One-hundred and eighty patients were randomized and 88 were assigned to the 
mesalazine, while 92 were assigned to placebo.2 The allocation of patients to each treatment 
group was concealed from those enrolling subjects and well as the subjects in the study.2 Patients 
received mesalazine or placebo three times daily over the 12-week period based on their assigned 
treatment group. Patients visited the study center every 2 weeks during the treatment period and 
their abdominal pain was assessed by their answer to the question “did you have satisfactory 
relief of your abdominal discomfort or pain during the last week?”.2 Patients were considered 




responders if they gave an affirmative answer to the question for more than 75% of the treatment 
period.2  
Table 1. Demographics and Characteristics of Included Studies 
Study Type #Pts Age(yrs) Inclusion Criteria Exclusion Criteria W/D Intervention 
Tuteja1 
(2012) 
RCT 20 18-75yrs Age 18-75, male or 
female, history of 




symptoms for more 
than 3 months, 
normal gross 
appearance of the 




previous diagnosis of or 
history compatible with 
IBS prior to acute 
gastroenteritis, clinically 
significant cardiac, 
pulmonary, hepatic or 
renal disorder, chronic 
gastrointestinal (GI) 
disorder, allergy to aspirin 














albumin, CRP, and 
negative celiac 





Any positive screening 
tests, Prior history of 
major abdominal surgery, 
liver or kidney 
impairment, or chronic 
ingestion of any anti-
inflammatory drugs or 
medications that can 
affect gut motility. 
Patients on unstable dose 
of SSRIs and TCAs for 
less than 3 months 
115 2 g of 
mesalazine qd 
for 1 week 
then bid for 
11 weeks 
1 RCT 180 18-65yrs 18-65yrs, patients 
with Rome III 
criteria for 
diagnosis of IBS 
 
Pregnant, breastfeeding, 
not using reliable 
contraception, NSAID 
use, corticosteroid use, 
mast cell stabilizers, the 
use of topic or systemic 
antibiotics in the last 
month, treatment with 
lactulose or with any 
compound that lowered 
the colonic pH and could 
prevent the release of the 
active moiety, major 
abdominal surgery, a 
history of inflammatory 
bowel disease or 
diverticular disease 
57 Mesalazine 
800mg tid for 
12 weeks 
 




According to the study 57 patients withdrew from the study prior to completion due to 
withdrawal of consent (14), adverse events (14), protocol violations (6), lost to follow-up (8), 
and other reasons (5).2 Dropouts that were due to inefficacy were treated as non-responders, 
while all other reasons were considered responders and missing data was ignored. 2 Worst-case 
analysis and best-case analysis led to similar conclusions.2 Due to this result the study concluded 
that the missing data had no effect on the end conclusion.2 The study included 172 patients in the 
intention to treat analysis, 86 in each treatment group.2 Twenty-eight patients in the mesalazine 
group were designated responders while 23 in the placebo group were designated responders.2 
The Number Needed to Treat (NNT) to achieve the treatment affect was 17. Although the results 
showed a greater number of responders in the mesalazine treatment group over placebo at 5.9%, 
the p-value was 0.404, which is not statistically significant, not less than or equal to 0.05.2 Table 
2 depicts the mean change from baseline of abdominal pain and discomfort for both treatment 
groups.  
Table 2. Descriptive Statistics by Treatment Group for Abdominal Pain/Discomfort Intensity2 
  Mesalazine (n=86) Placebo (n=86) 
Mean (SD) Baseline (week 2) 4.59 (2.54) 4.50 (2.34) 
Mean change versus 
baseline (SD) 
End of treatment -1.07 (2.54) -1.21 (2.36) 
 
Tuteja et al. performed a randomised control trial comparing the use mesalamine 1.6 g 
orally twice daily for 12 weeks to placebo in decreasing abdominal pain in patients with post-
infective IBS.1 Blinding was achieved for this study.1 The population for this study were adults 
18-75 years of age with diagnosed IBS after an acute case of gastroenteritis.1 Fifteen of the 




participants were returned missionaries or international travelers who developed IBS after acute 
gastroenteritis while abroad.1 Further inclusion and exclusion criteria are listed in Table 1. 
Twenty patients were randomized and 10 were allocated to each treatment group, mesalamine 
and placebo.1 Three patients withdrew from the study before completion.1 Two from the 
mesalamine treatment group and one from placebo.1 The results from these patients were 
excluded.1 Level of pain was recorded for 7 days at baseline and then every 4 weeks.1 The mean 
change from baseline is recorded in Table 3.  
Table 3. Mean Change in Abdominal Pain from Baseline per Treatment Group after 12 Weeks of 
Therapy with 95% CI1 




The mean change from baseline was superior with use of mesalamine when compared to 
placebo.1 However, these results were not statistically significant since the p-value was 0.83.1        
 Lam et al. performed a 12-week randomized control trial evaluating the decrease in 
abdominal pain in patients with IBS-D when treated with mesalamine 2 g twice daily compared 
to placebo.7 Participants and those enrolling participants were blinded to allocation of treatment 
group.7 The population for this study consisted of patients 18-75 with diagnosed IBS-D.7 Other 
inclusion and exclusion criteria are listed in Table 1. One-hundred and thirty-six patients were 
randomized and 68 were assigned to each treatment group.7 Twenty-one patients’ results were 
not analyzed and were considered dropouts.7 Reasons for dropouts included withdrawal of 
consent, loss to follow up, and adverse events.7 This resulted in 57 patients in the mesalazine 
treatment group and 58 in the placebo control group.7 Daily pain levels were recorded by patients 




in a daily symptom diary.7 At the end of treatment, weeks 11 and 12, the mean pain score was 
taken and can be seen in Table 4. The table shows that the end of trial difference between groups 
was -0.6 in favor of placebo, with a p-value of 0.83.7 This showed that mesalazine was not 
superior to placebo at decreasing abdominal pain in patients with IBS-D.7 
Table 4. Mean Abdominal Pain Score per Treatment Group at Weeks 11-12 (95% CI)7 






IBS is the most common functional bowel disorder encountered in provider practice, but 
the disorder pathophysiology is not clearly understood. Current treatment consists of treating 
whatever symptoms may arise without knowing the underlying cause to prevent symptoms from 
occurring. Inflammation is believed to play a role in the pathophysiology of IBS especially after 
cases of acute gastroenteritis.1,2,7  Mesalazine is used in ulcerative colitis to decrease 
prostaglandins, which in turn decreases inflammation and symptoms associated with the 
disease.1 Physicians, physician assistants and other practitioners already prescribe mesalazine for 
this purpose so its safety of use to an extent has already been established. The link between 
inflammation and IBS could be the key to treating the underlying cause of symptoms and 
decreasing them, namely abdominal pain. 
Only two of the three studies discussed in this review showed a superior decrease in 
abdominal pain with use of mesalamine when compared to placebo. Even so, these results were 
not statistically significant. One limitation to these studies are the study populations. The study 
done by Tuteja et al. did not specify the ethnicity of its subjects, which could play a role in 
determining if mesalazine is more effective at decreasing abdominal pain in certain ethnicities 




when compared to others.1 The study also consisted of missionary travelers who’s IBS started 
after an acute case of gastroenteritis which is not completely generalizable to the entire 
population of IBS patients.1 Also it would be helpful for mean ages to be provided instead of 
simply the age range for the inclusion criteria and the median age. This would help to specify 
further what population has been target by the study. Another issue with the population is that is 
consisted of 11 men and 6 women, who were not evenly distributed across treatment groups.1 
The difference in the two treatment groups could affect the results of the study. The population 
for this study was also quite small with only 17 participants.1 A larger study population would 
certainly be beneficial. Lastly the pharmacist was not blinded to the assigning of participants. 
This could certainly have affected the outcome of the study.1 
  The population for the study done by Lam et al. consisted predominantly of middle-aged 
females, but the allocation was evenly distributed among the two treatment groups.7 Extended 
demographics for these participants would also have been helpful towards analyzing the 
treatment effect on that specific population. The study population for the study performed by 
Barbara et al. consists of a majority of middle-aged Caucasian females. Although this study is 
highly specific to that population, it is not generalizable to the population as a whole.     
Another issue that can be foreseen with all 3 studies is that they were outpatient trials 
where patients were not supervised for the entirety of the study.1,2,7 The results were dependent 
on the patient’s compliance with the study protocol, but there was no mention of a method 
ensuring patients adhered to the study protocol. The method of assessing the level of pain also 
had the potential to skew results as in Barbara et al.2 It is more standardized to use a 10-point 
visual analog scale that does not sway patients to a specific response based on the words used to 
describe the level of pain.  




An additional issue that arose in the Barbara et al. study is that there was a large number 
of dropouts in the study. Patients who did not complete the entire 12-week treatment were 
considered as having a major protocol violation.2 Also the study states that all dropouts due to 
inefficacy were considered non-responders while all other dropouts were considered responders 
and the missing data was ignored.2 This could have a significant impact in the outcome of the 
study. Lastly both Barbara et al and Lam et al allowed the used of medications traditionally used 
to treat IBS during the course of the study.2,7 Discontinuing traditional treatments prior to and 
during the duration of the entire study may demonstrate the clarity of the effect of mesalamine of 
abdominal pain in patients with IBS.  
CONCLUSIONS 
 Based on the three studies discussed in this review mesalamine does not decrease 
abdominal pain in adults with IBS superior to placebo. Two of the studies show showed a 
superior decrease in abdominal with use of mesalamine when compared to placebo, while one 
demonstrated that mesalamine was not superior to placebo, but the results were not statistically 
significant and did not give the confidence that these results were not simply due to chance.1,2,7 
Issues arose in these studies including the protocols used, the adherence of patients to these 
protocols, and other variables that were present that could skew the outcomes of the studies. 
Larger studies are needed to assess the effect that mesalamine therapy has in reducing abdominal 
pain in patients with IBS. It would also be important to limit the number of confounding 
variables to determine the true treatment effect of mesalamine on abdominal pain. Lastly it 
would be beneficial for patients to participate in an inpatient study where they could be observed 
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